2 March 2015
EMA/COMP/38966/2015
Committee for Orphan Medicinal Products (COMP)

# Committee for Orphan Medicinal Products (COMP) meeting report on the review of applications for orphan designation

February 2015

The Committee for Orphan Medicinal Products held its 164th plenary meeting on 10-12 February 2015.

## Orphan medicinal product designation

### Positive opinions

The COMP adopted 22 positive opinions recommending the following medicines for designation as orphan medicinal products to the European Commission (EC):

1. Opinions adopted at the second COMP discussion, following the sponsor's response to the COMP list of questions:

- 5'-$A_S C_S A_S T_S C_S A_S G_S T_S C_S T_S G_S A_S U_S A_S A_S G_S C_S T_S$A-3' for treatment of Alport syndrome, CTI Clinical Trial and Consulting Services Europe GmbH
- 6-ethoxy-7-methoxy-2-(2-methylsulfanylphenyl)-3,1-benzoxazin-4-one for treatment of Netherton syndrome, Sixera Pharma AB
- Human plasma-derived alpha-1 proteinase inhibitor for treatment of graft-versus-host disease, Richardson Associates Regulatory Affairs Ltd
- Recombinant human club cell 10 KDa protein for prevention of bronchopulmonary dysplasia, RLM Consulting
- Tideglusib for treatment of fragile X syndrome, QRC Consultants Ltd.

2. Opinions adopted at the first COMP discussion:

- [5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-trifluoromethyl-pyridin-3-ylmethyl)-amine hydrochloride for treatment of tenosynovial giant cell tumour, localised and diffuse type, Daiichi Sankyo Development Ltd
- 5,10,15,20-tetrakis(2,6-difluoro-3-N-methylsulfamoylphenyl)bacteriochlorin for treatment of biliary tract cancer, Luzitin S.A.

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
**Telephone** +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5555
**Send a question via our website** www.ema.europa.eu/contact

- Adeno-associated viral vector serotype 9 containing the human glucocerebrosidase gene for treatment of Gaucher disease, Gauchers Association
- Autologous adipose tissue-derived stromal vascular fraction cells for treatment of systemic sclerosis, Assistance Publique Hôpitaux de Marseille
- Chimeric 2'-O-(2-methoxyethyl) modified oligonucleotide targeted to huntingtin RNA for treatment of Huntington's disease, Isis USA Ltd
- Enoxacin for treatment of amyotrophic lateral sclerosis, Impasara Ltd
- Ex-vivo-expanded autologous human keratinocytes containing epidermal stem cells transduced with a *COL17A1*-encoding retroviral vector for treatment of epidermolysis bullosa, Chiesi Farmaceutici S.p.A.
- Ex-vivo-expanded autologous human keratinocytes containing epidermal stem cells transduced with a *COL7A1*-encoding retroviral vector for treatment of epidermolysis bullosa, Chiesi Farmaceutici S.p.A.
- Ex-vivo-expanded autologous human keratinocytes containing epidermal stem cells transduced with a *LAMB3*-encoding retroviral vector for treatment of epidermolysis bullosa, Chiesi Farmaceutici S.p.A.
- Gallium ($^{68}$Ga)-edotreotide for diagnosis of gastro-entero-pancreatic neuroendocrine tumours, Advanced Accelerator Applications SA
- Human reovirus type 3 Dearing strain for treatment of ovarian cancer, Oncolytics Biotech (UK) Limited
- Humanised anti-folate receptor 1 monoclonal antibody conjugated to maytansinoid DM4 for treatment of ovarian cancer, ImmunoGen Europe Limited
- Lenvatinib for treatment of hepatocellular carcinoma, Eisai Europe Limited
- Melphalan flufenamide for treatment of plasma cell myeloma, Oncopeptides AB
- Recombinant human monoclonal antibody binding to vascular adhesion protein-1 for treatment of primary sclerosing cholangitis, Biotie Therapies Corp
- Sodium 3-[(4aR,6R,7R,7aS)-7-hydroxy-2-oxido-2-sulfanylidene-4a,6,7,7a-tetrahydro-4H-furo [3,2-d][1,3,2] dioxaphosphinin-6-yl]-2-bromo-6-phenyl-5H-imidazo[1,2-a]purin-9-one for treatment of retinitis pigmentosa, Universitätsklinikum Tübingen (UKT)
- Trientine tetrahydrochloride for treatment of Wilson's disease, GMP-Orphan SAS

Revision of the COMP opinions:

- Allogeneic CD4+ and CD8+ T lymphocytes ex vivo incubated with synthetic peptides of the viral antigens of cytomegalovirus, adenovirus and Epstein-Barr virus for treatment of adenovirus infection following haematopoietic stem cell transplantation, Miltenyi Biotec GmbH
- Allogeneic CD4+ and CD8+ T lymphocytes ex vivo incubated with synthetic peptides of the viral antigens of cytomegalovirus, adenovirus and Epstein-Barr virus for treatment of Epstein-Barr virus infection following haematopoietic stem cell transplantation, Miltenyi Biotec GmbH

Public summaries of opinions will be available on the EMA website following adoption of the respective decisions on orphan designation[1] by the European Commission.

### Negative opinion

The COMP adopted 1 negative opinion recommending the refusal of the orphan medicinal product designation for a product for treatment of uremic pruritus. The sponsor was informed about the possibility to appeal.

### Lists of questions

The COMP adopted 19 lists of questions on initial applications. These applications will be discussed again at the next COMP meeting prior to the adoption of an opinion.

### Oral hearings

11 oral hearings took place.

### Withdrawals of applications for orphan medicinal product designation

The COMP noted that 7 applications for orphan medicinal product designation were withdrawn.

### Detailed information on the orphan designation procedures

An overview of orphan designation procedures since 2000 is provided in Annex 1.

The list of medicinal products for which decisions on orphan designation have been given by the European Commission since the last COMP meeting is provided in Annex 2.

## Applications for marketing authorisation for orphan medicinal products

Details of those designated orphan medicinal products that have been subject of a new European Union (EU) marketing authorisation application through the centralised procedure since the last COMP plenary meeting are provided in Annex 3.

Details on the authorised orphan medicinal products can be found on the EMA website.

## Other matters

The main topics addressed during the meeting related to:

- Protocol assistance advice

## Upcoming meetings

- The 165th meeting of the COMP will be held on 17-19 March 2015

[1] Details of all orphan designations granted to date by the European Commission are entered in the EU Register of Orphan Medicinal Products

## Note

This monthly report, together with other information on the work of the European Medicines Agency, can be found on the EMA website: www.ema.europa.eu

## Contact our press officer

Monika Benstetter

Tel. +44 (0)20 3660 8427, E-mail: press@ema.europa.eu

# Annex 1

**Overview for orphan medicinal product designation procedure since 2000**

| Year | Applications submitted | Applications discussed in reporting year | Positive COMP opinions | Applications withdrawn | Final negative COMP opinions | EC designations | Orphan medicinal products[2] authorised | Orphan designations included in authorised therapeutic indication |
|---|---|---|---|---|---|---|---|---|
| 2015 | 24 | 66 | 41 (62%) | 25 (38%) | 0 (0%) | 22 | 3 | 3 |
| 2014 | 329 | 259 | 196 (76%) | 61 (24%) | 2 (1%) | 187 | 15 | 16 |
| 2013 | 201 | 197 | 136 (69%) | 60 (30%) | 1 (1%) | 136 | 7 | 8 |
| 2012 | 197 | 192 | 139 (72%) | 52 (27%) | 1 (1%) | 148 | 10 | 12 |
| 2011 | 166 | 158 | 111 (70%) | 45 (29%) | 2 (1%) | 107 | 5 | 5 |
| 2010 | 174 | 176 | 123 (70%) | 51 (29%) | 2 (1%) | 128 | 4 | 4 |
| 2009 | 164 | 136 | 113 (83%) | 23 (17%) | 0 (0%) | 106 | 9 | 9 |
| 2008 | 119 | 118 | 86 (73%) | 31 (26%) | 1 (1%) | 73 | 6 | 7 |
| 2007 | 125 | 117 | 97 (83%) | 19 (16%) | 1 (1%) | 98 | 13 | 13 |
| 2006 | 104 | 103 | 81 (79%) | 20 (19%) | 2 (2%) | 80 | 9 | 11 |
| 2005 | 118 | 118 | 88 (75%) | 30 (25%) | 0 (0%) | 88 | 4 | 4 |
| 2004 | 108 | 101 | 75 (74%) | 22 (22%) | 4 (4%) | 73 | 6 | 6 |
| 2003 | 87 | 96 | 54 (56%) | 41 (43%) | 1 (1%) | 55 | 5 | 5 |
| 2002 | 80 | 75 | 43 (57%) | 30 (40%) | 2 (3%) | 49 | 4 | 4 |
| 2001 | 83 | 90 | 62 (70%) | 27 (29%) | 1 (1%) | 64 | 3 | 3 |
| 2000 | 72 | 32 | 26 (81%) | 6 (19%) | 0 (0%) | 14 | 0 | 0 |
| **Total** | **2151** | **2034** | **1471 (72%)** | **543 (27%)** | **20 (1%)** | **1428** | **103** | **110** |

[2] Number of authorised orphan medicinal products may cover more than one orphan designation

# Annex 2

**Medicinal products granted a European Union designation as orphan medicinal product by the European Commission since the January 2015 COMP monthly report**

| Active substance | Orphan indication | Sponsor | COMP opinion date | EC designation date |
|---|---|---|---|---|
| 2'-*O*-methyl phosphorothioate RNA oligonucleotide, 5'-$m^5$CUG$m^5$CUG$m^5$CUG$m^5$CUG$m^5$CUG$m^5$CUG$m^5$CUG-3' | Treatment of Huntington's disease | Prosensa Therapeutics B.V. | 9 January 2015 | 12 February 2015 |
| 3-[2-(4-carbamimidoyl-phenylcarbamoyl)-5-methoxy-4-vinyl-phenyl]-6-(cyclopropylmethyl-carbamoyl)-pyridine-2-carboxylic acid | Treatment of hereditary angioedema | BioCryst UK Ltd. | 9 January 2015 | 12 February 2015 |
| 505 amino acid protein, corresponding to amino acids 2-506 of the wild type human histidyl-tRNA synthetase | Treatment of facioscapulohumeral muscular dystrophy | Voisin Consulting S.A.R.L. | 9 January 2015 | 12 February 2015 |
| 5-hydroxymethyl-2-furfural | Treatment of sickle cell disease | Baxter Innovations GmbH | 9 January 2015 | 12 February 2015 |
| A lentiviral vector pseudotyped by the Indiana serotype of the vesicular stomatitis virus G protein encoding an antigen derived from the Tax, HBZ, p12I and p30II HTLV-1 proteins | Treatment of adult T-cell leukaemia/lymphoma | THERAVECTYS | 11 December 2014 | 15 January 2015 |
| A lentiviral vector pseudotyped by the New-Jersey serotype of the vesicular stomatitis virus G protein encoding an antigen derived from the Tax, HBZ, p12I and p30II HTLV-1 proteins | Treatment of adult T-cell leukaemia/lymphoma | THERAVECTYS | 11 December 2014 | 15 January 2015 |
| Adeno-associated viral vector serotype 8 containing the human factor VII gene | Treatment of congenital factor VII deficiency | Professor Edward G. Tuddenham | 11 December 2014 | 15 January 2015 |

| Active substance | Orphan indication | Sponsor | COMP opinion date | EC designation date |
|---|---|---|---|---|
| Adenoviral vector serotype 5 containing the vascular endothelial growth factor D isoform (preprocessed short form) from a CMV promoter | Treatment of placental insufficiency | Magnus Invention Management Ltd | 11 December 2014 | 15 January 2015 |
| Allogeneic CD4+ and CD8+ T lymphocytes ex vivo incubated with synthetic peptides of the viral antigens of cytomegalovirus, adenovirus and Epstein-Barr virus | Treatment of cytomegalovirus infection following haematopoietic stem cell transplantation | Miltenyi Biotec GmbH | 9 January 2015 | 12 February 2015 |
| Allogeneic peripheral blood mononuclear cells induced to an early apoptotic state | Prevention of graft-versus-host disease | Richardson Associates Regulatory Affairs Ltd | 11 December 2014 | 15 January 2015 |
| Allogeneic, umbilical cord blood-derived, ex vivo-expanded, haematopoietic CD133+ cells / allogeneic, umbilical cord blood-derived, non-expanded, haematopoietic CD133- cells | Treatment of acute myeloid leukaemia | Regulatory Resources Group Ltd | 11 December 2014 | 15 January 2015 |
| Alvocidib | Treatment of acute myeloid leukaemia | Theorem Clinical Research GmbH | 9 January 2015 | 12 February 2015 |
| Ceftriaxone | Treatment of spinocerebellar ataxia | Ospedale San Raffaele s.r.l. | 11 December 2014 | 15 January 2015 |
| Chimeric fusion protein of recombinant human alpha-N-acetylglucosaminidase and human insulin-like growth factor 2 | Treatment of mucopolysaccharidosis type IIIB (Sanfilippo B syndrome) | BioMarin Europe Ltd. | 11 December 2014 | 15 January 2015 |
| Chimeric group B adenovirus (11p/3) with deletions in the E3 and E4 regions | Treatment of ovarian cancer | PsiOxus Therapeutics Ltd | 9 January 2015 | 12 February 2015 |
| Chimeric monoclonal antibody to O-acetyl-GD2 antigen | Treatment of neuroblastoma | Atlab Pharma SAS | 11 December 2014 | 15 January 2015 |
| Emtricitabine | Treatment of Aicardi-Goutières syndrome | Dr Yanick Crow | 11 December 2014 | 15 January 2015 |
| Fibrinogen-coated albumin spheres | Treatment of Ebola virus disease | Fibreu Limited | 9 January 2015 | 12 February 2015 |

| Active substance | Orphan indication | Sponsor | COMP opinion date | EC designation date |
|---|---|---|---|---|
| Herpes simplex type 1 virus containing cellular *B-myb* gene as tumour-specific promoter | Treatment of pancreatic cancer | Karcinolys S.A.S | 11 December 2014 | 15 January 2015 |
| Humanised Fc engineered monoclonal antibody against CD19 | Treatment of diffuse large B-cell lymphoma | MorphoSys AG | 11 December 2014 | 15 January 2015 |
| *Lactobacillus reuteri* | Prevention of necrotising enterocolitis | Infant Bacterial Therapeutics AB | 9 January 2015 | 12 February 2015 |
| Mazindol | Treatment of narcolepsy | HAC Pharma | 9 January 2015 | 12 February 2015 |
| Myriocin | Treatment of retinitis pigmentosa | Nanovector s.r.l. | 9 January 2015 | 12 February 2015 |
| N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine disulphate salt | Treatment of progressive supranuclear palsy | AlzProtect sas | 9 January 2015 | 12 February 2015 |
| Nitroglycerin | Treatment of systemic sclerosis | Covis Pharma S.à.r.l. | 9 January 2015 | 12 February 2015 |
| N-methyl-4-({4-[({3-methyl(methylsulfonyl)aminopyrazin-2-yl}methyl)amino]-5-(trifluoromethyl)pyrimidin-2-yl}amino)benzamide hydrochloride | Treatment of ovarian cancer | TMC Pharma Services Ltd | 11 December 2014 | 15 January 2015 |
| Olaratumab | Treatment of soft tissue sarcoma | Eli Lilly Nederland B.V. | 9 January 2015 | 12 February 2015 |
| Pegylated recombinant arginine deiminase | Treatment of malignant mesothelioma | Designerx Europe Limited | 11 December 2014 | 15 January 2015 |
| Pentosan polysulfate sodium | Treatment of interstitial cystitis | Dr Ulrich Granzer | 11 December 2014 | 15 January 2015 |
| Ponatinib hydrochloride | Treatment of gastrointestinal stromal tumours | ARIAD Pharma Ltd | 11 December 2014 | 15 January 2015 |
| Recombinant human alkaline phosphatase | Treatment of hypophosphatasia | AM-Pharma BV | 11 December 2014 | 15 January 2015 |
| Recombinant human aspartylglucosaminidase | Treatment of aspartylglucosaminuria | ACE Biosciences A/S | 11 December 2014 | 15 January 2015 |

| Active substance | Orphan indication | Sponsor | COMP opinion date | EC designation date |
|---|---|---|---|---|
| Recombinant human glutamate oxaloacetate transaminase 1 | Treatment of glioma | Impasara Ltd | 9 January 2015 | 12 February 2015 |
| Sevuparin sodium | Treatment of sickle cell disease | Dilaforette AB | 9 January 2015 | 12 February 2015 |
| Sodium thiosulfate | Treatment for calciphylaxis | Hope Pharmaceuticals, Ltd | 11 December 2014 | 15 January 2015 |
| Sodium valproate | Treatment of Wolfram syndrome | Alan Boyd Consultants Ltd | 11 December 2014 | 15 January 2015 |
| Synthetic signal peptide of human mucin-1 (amino acids 1-21) | Treatment of plasma cell myeloma | Richardson Associates Regulatory Affairs Ltd | 11 December 2014 | 15 January 2015 |
| Tenofovir disoproxil fumarate | Treatment of Aicardi-Goutières syndrome | Dr Yanick Crow | 11 December 2014 | 15 January 2015 |
| Ulocuplumab | Treatment of acute myeloid leukaemia | Bristol-Myers Squibb Pharma EEIG | 9 January 2015 | 12 February 2015 |

# Annex 3

**Designated orphan medicinal products that have been subject of a new European Union marketing authorisation application under the centralised procedure since the January 2015 COMP monthly report**

| Active substance | Designated orphan indication | Sponsor/applicant | EU designation number |
|---|---|---|---|
| Cysteamine hydrochloride | Treatment of cystinosis | Lucane Pharma | EU/3/14/1341 |
| Ibrutinib | Treatment of lymphoplasmacytic lymphoma | Janssen-Cilag International NV | EU/3/14/1264 |
| Lenalidomide | Treatment of mantle cell lymphoma | Celgene Europe Limited | EU/3/11/924 |